/PRNewswire/ DiaCarta, Inc., a leading innovator in precision medicine diagnostic biomarker assays, announced today that DiaCarta received US FDA 510(k).
/PRNewswire/ DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology and infectious disease tests announced today.
/PRNewswire/ DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the.
Share this article
Share this article
RICHMOND, Calif., April 22, 2021 /PRNewswire/ DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced the publication of a study entitled A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR in
MedRxiV (https://doi.org/10.1101/2021.04.01.21254484) that demonstrates the enhanced sensitivity and specificity using its proprietary XNA based Molecular Clamping Technology that uses innovative synthetic Xenonucleic acid molecular oligomers (XNA) that hybridize with target wild-type DNA sequences, acting as molecular clamps, to enable the accurate amplification of mutant sequences only, using quantitative real-time polymerase chain reactions (qPCR).